AC
BDRX

Armistice Capital’s Biodexa Pharmaceuticals BDRX Stock Holding History

Armistice Capital’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.1K Sell
14,809
-4,695
-24% -$15.8K ﹤0.01% 320
2026
Q1 		$60.3K Sell
19,504
-496
-2% -$3.49K ﹤0.01% 249
2025
Q4 		$227K Buy
+20,000
New +$569K ﹤0.01% 332
2023
Q1 		– Sell
-1
Closed -$381K – 230
2022
Q4 		$381K Buy
+1
New +$627K 0.01% 147

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Armistice Capital's BDRX Position: Q2 2026 in Review

Armistice Capital reduced its Biodexa Pharmaceuticals (BDRX) stake by 24% in Q2 2026, selling an estimated $15.8K and leaving 14,809 shares worth $43.1K. The position accounts for ﹤0.01% of the portfolio, ranked #320.

Armistice Capital first reported a position in BDRX in Q4 2022 and has held it in 4 quarters since. The position peaked at $381K in Q4 2022. 8 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • Armistice Capital held 14,809 shares of Biodexa Pharmaceuticals worth $43.1K as of Q2 2026.
  • Armistice Capital sold 4,695 Biodexa Pharmaceuticals shares in Q2 2026, an estimated $15.8K.
  • Biodexa Pharmaceuticals made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #320 holding.
  • Armistice Capital first reported a position in Biodexa Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • Armistice Capital's Biodexa Pharmaceuticals position peaked at $381K in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.